DF/HCC Program Affiliation

Leader, Breast Cancer Program
Member, Cancer Epidemiology Program

DF/HCC Associations

Member, Clinical Science Coordinating Committee
Principal Investigator, DF/HCC Breast SPORE
Member, Center Scientific Council

Research Abstract

I am working in the area of breast cancer genetics, both at a biological and clinical level. Clinically, I am interested in the application of genetic susceptibility testing in actual practice. More fundamentally, I am interested in the genes which confer susceptibility to breast cancer. Previous work has focused on BRCA1 and BRCA2, but future investigation will be directed toward the role of DNA damage and breast cancer risk.

Publications

• Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, Ryan PD, Come SE, Burstein HJ, Lesnikoski BA, Kamma M, Friedman PN, Gelman R, Iglehart JD, Winer EP. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 2007 Feb 15; 13(4):1198-207
  PMID: 17317830
• Chang SB, Miron P, Miron A, Iglehart JD. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells. J Surg Res 2007 Mar; 138(1):37-44
  PMID: 17109887
• Shi Q, Harris LN, Lu X, Li X, Hwang J, Gentleman R, Iglehart JD, Miron A. Declining plasma fibrinogen alpha fragment identifies HER2-positive breast cancer patients and reverts to normal levels after surgery. J Proteome Res 2006 Nov; 5(11):2947-55
  PMID: 17081046
• Biswas DK, Iglehart JD. Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer. J Cell Physiol 2006 Dec; 209(3):645-52
  PMID: 17001676
• Wang ZC, Buraimoh A, Iglehart JD, Richardson AL. Genome-Wide Analysis for Loss of Heterozygosity in Primary and Recurrent Phyllodes Tumor and Fibroadenoma of Breast using Single Nucleotide Polymorphism Arrays. Breast Cancer Res Treat 2006 Apr 27;
  PMID: 16642273
• Zhang X, Lu X, Shi Q, Xu XQ, Leung HC, Harris LN, Iglehart JD, Miron A, Liu JS, Wong WH. Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data. BMC Bioinformatics 2006; 7:197
  PMID: 16606446
• Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, Liao X, Iglehart JD, Livingston DM, Ganesan S. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 2006 Feb; 9(2):121-32
  PMID: 16473279
• Davis PL, Miron A, Andersen LM, Iglehart JD, Marks JR. Isolation and initial characterization of the BRCA2 promoter. Oncogene 1999 Oct 28; 18(44):6000-12
  PMID: 10557089
• Iglehart JD, Miron A, Rimer BK, Winer EP, Berry D, Shildkraut MJ. Overestimation of hereditary breast cancer risk. Ann Surg 1998 Sep; 228(3):375-84
  PMID: 9742920
• Vaughn JP, Cirisano FD, Huper G, Berchuck A, Futreal PA, Marks JR, Iglehart JD. Cell cycle control of BRCA2. Cancer Res 1996 Oct 15; 56(20):4590-4
  PMID: 8840967